Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Short-term Investments (2020 - 2022)

SOPHiA GENETICS's Short-term Investments history spans 3 years, with the latest figure at $17.3 million for Q4 2022.

  • On a quarterly basis, Short-term Investments fell 76.08% to $17.3 million in Q4 2022 year-over-year; TTM through Dec 2022 was $17.3 million, a 76.08% decrease, with the full-year FY2022 number at $17.3 million, down 76.08% from a year prior.
  • Short-term Investments hit $17.3 million in Q4 2022 for SOPHiA GENETICS, down from $72.4 million in the prior quarter.
  • Over the last five years, Short-term Investments for SOPH hit a ceiling of $72.4 million in Q4 2021 and a floor of $17.3 million in Q4 2022.
  • Historically, Short-term Investments has averaged $37.5 million across 3 years, with a median of $22.7 million in 2020.
  • Biggest five-year swings in Short-term Investments: soared 218.47% in 2021 and later plummeted 76.08% in 2022.
  • Tracing SOPH's Short-term Investments over 3 years: stood at $22.7 million in 2020, then soared by 218.47% to $72.4 million in 2021, then plummeted by 76.08% to $17.3 million in 2022.
  • Business Quant data shows Short-term Investments for SOPH at $17.3 million in Q4 2022, $72.4 million in Q4 2021, and $22.7 million in Q4 2020.